GlycoNex (ROCO:4168) Construction In Progress: NT$0.00 Mil (As of Dec. 2025)


ROCO:4168 GlycoNex Inc ROCO:4168
56 GF Score
Price NT$25.50
GF Value NT$74.67
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is GlycoNex Construction In Progress?

GlycoNex ROCO:4168 +0.79% 56 Construction In Progress is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:4168 with a GF Score™ of 56/100 and a GF Value™ of NT$74.67 (Significantly Undervalued). The stock has 2 warning signs investors should review.

GlycoNex Construction In Progress Historical Data

* Premium members only.

The historical data trend for GlycoNex's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex Construction In Progress Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GlycoNex Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:4168
56GF Score
GlycoNex Inc ROCO:4168
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlycoNex Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of NT$0.00 Mil mean?
GlycoNex (ROCO:4168) has a Construction In Progress of NT$0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on GlycoNex and its competitors.
Is GlycoNex's Construction In Progress too high?
GlycoNex's current Construction In Progress is NT$0.00 Mil. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Construction In Progress compare to VRTX and REGN?
GlycoNex's Construction In Progress of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on GlycoNex and its competitors. GlycoNex's current Construction In Progress is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$74.67, compared to a current price of NT$25.50 — trading 65.8% below its estimated fair value. The current Construction In Progress is NT$0.00 Mil. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Construction In Progress is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$25.50 is trading 65.8% below its estimated GF Value™ of NT$74.67. GuruFocus considers GlycoNex to be Significantly Undervalued.

Key valuation signals for ROCO:4168:

  • Construction In Progress: NT$0.00 Mil
  • GF Value™: NT$74.67 vs. price of NT$25.50 (65.8% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score

Get the complete analysis for ROCO:4168

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.50
Price
NT$74.67
GF Value